Trial Profile

Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination With FOLFIRI for the Treatment of Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 24 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Lunresertib (Primary)
Indications Colorectal cancer; Gastrointestinal cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions
Acronyms MINOTAUR
Sponsors Repare Therapeutics

Most Recent Events

17 Jun 2025 Status changed from active, no longer recruiting to discontinued as per sponsor decision
30 Jun 2024 According to a Repare Therapeutics media release, data from this trial presented at the ESMO GI Cancers Congress in June 2024.
26 Jun 2024 According to a Repare Therapeutics media release, 38 patients were enrolled in the clinical trial as of May 2, 2024, the cutoff date for the data presented at ESMO GI Cancers Congress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com